Literature DB >> 9369845

Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi.

J H Rand1, X X Wu, S Guller, J Scher, H A Andree, C J Lockwood.   

Abstract

OBJECTIVES: The mechanism by which antiphospholipid antibodies are associated with pregnancy loss and thromboembolism has not been established. We previously showed that annexin-V, a phospholipid-binding protein with potent anticoagulant activity, is present on the apical membranes of the syncytiotrophoblasts that line placental villi and that this protein is reduced, by immunohistochemistry, on placentas of patients with antiphospholipid antibodies. We therefore investigated whether annexin-V in apical membranes of placental villi is quantitatively reduced by antiphospholipid antibody immunoglobulin G. STUDY
DESIGN: Placentas were obtained from an index patient with antiphospholipid syndrome with intrauterine growth restriction and from a patient with an uncomplicated pregnancy who were both delivered by cesarean section. Apical villous membranes were isolated and annexin-V levels were measured by enzyme-linked immunosorbent assay. We then studied the effects of antiphospholipid immunoglobulin G on placental villous apical annexin-V in vitro. Antiphospholipid immunoglobulin G was isolated from the sera of five different patients with antiphospholipid antibody syndrome along with five paired control immunoglobulin Gs. Short-term cultures were established from normal placental villi and were exposed to the antibodies, after which isolated apical membranes and culture media were immunoassayed for annexin-V levels.
RESULTS: Measurements of apical membrane-associated annexin-V from the antiphospholipid placenta showed significantly less apical membrane-associated annexin-V than did the normal placenta (mean +/- SEM: 4.9 +/- 0.4 micrograms/gm villi for antiphospholipid placenta vs 10.2 +/- 0.6 micrograms/gm villi for control, p < 0.001, n = 4). Exposure of placental villous cultures to five different antiphospholipid immunoglobulin Gs for 24 hours resulted in significant reduction of the levels of apical membrane annexin-V (mean +/- SEM: 3.9 +/- 0.3 micrograms/gm villi) compared with paired controls (5.1 +/- 0.3 micrograms/gm villi, p = 0.02). Villi incubated with the different antiphospholipid immunoglobulin Gs had significantly less annexin-V in conditioned media (mean +/- SEM: 45.1 +/- 4.9 ng/gm villi) compared with the paired normal immunoglobulin G control levels (72.6 +/- 11.4 ng/gm villi, p = 0.03).
CONCLUSIONS: Antiphospholipid immunoglobulin G reduces the levels of syncytiotrophoblast apical membrane-associated annexin-V in placental villi and the release of annexin-V into surrounding media. Reduction of this anticoagulant protein at the maternal-fetal interface may account for the pregnancy loss observed in patients with antiphospholipid syndrome. Short-term culture of placental villi may offer an in vitro model to further study the mechanism of this effect of antiphospholipid antibodies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369845     DOI: 10.1016/s0002-9378(97)70294-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  The haplotype M2 of the ANXA5 gene is not associated with antitrophoblast antibodies.

Authors:  Nina Rogenhofer; Laura Engels; Nadja Bogdanova; Frank Tüttelmann; Arseni Markoff; Christian J Thaler
Journal:  J Assist Reprod Genet       Date:  2013-03-27       Impact factor: 3.412

Review 2.  What is antiphospholipid syndrome?

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

3.  Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome.

Authors:  B de Laat; R H W M Derksen; I J Mackie; M Roest; S Schoormans; B J Woodhams; P G de Groot; W L van Heerde
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

Review 4.  The pathogenic role of annexin-V in the antiphospholipid syndrome.

Authors:  J H Rand
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

5.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

6.  Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Pojen P Chen; Keith R McCrae; Edwin G Bovill; Douglas J Taatjes
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 7.  Predictors of pregnancy outcome in antiphospholipid syndrome: a review.

Authors:  Sara De Carolis; Angela Botta; Stefania Santucci; Serafina Garofalo; Carmelinda Martino; Alessandra Perrelli; Silvia Salvi; Sergio Ferrazzani; Leonardo Caforio; Giovanni Scambia
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 8.  Pathophysiology of the antiphospholipid antibody syndrome.

Authors:  Rohan Willis; Silvia S Pierangeli
Journal:  Auto Immun Highlights       Date:  2011-03-24

9.  Recurrent IVF failure and hereditary thrombophilia.

Authors:  Leila Safdarian; Zahra Najmi; Ashraf Aleyasin; Marzieh Aghahosseini; Mandana Rashidi; Sara Asadollah
Journal:  Iran J Reprod Med       Date:  2014-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.